AG-7088. Anti-rhinovirus drug HRV 3C protease inhibitor

Drugs of the Future

Volumn 25, Issue 1, 2000, Pages 9-15

  Graul, A ^a   Castaner J ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; APO 501; LY 338387; LY 343814; LY 353352; LY 368177; M 160; PLECONARIL; PROTEINASE INHIBITOR; RECOMBINANT INTERCELLULAR ADHESION MOLECULE 1; RUPINTRIVIR; UNCLASSIFIED DRUG; WIN 61209;

ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL TRIAL; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; HUMAN; HUMAN RHINOVIRUS;

EID: 0343114370     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2000.025.01.563720     Document Type: Article

References (17)

1. Dragovich, P.S., Marakovits, J.T., Prins, T.J., Tikhe, J.G., Webber, S.E., Zhou, R., Johnson, T.O. (Agouron Pharmaceuticals, Inc.). Antipicornaviral cpds., their preparation and use. WO 9957135.
2. Dragovich, P.S., Prins, T.J., Zhou, R., Fuhrman, S.A., Patick, A.K., Matthews, D.A., Ford, C.E., Meador, J.W. III, Ferre, R.A., Worland, S.T. Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 3. Structure-activity studies of ketomethylene-containing peptidomimetics. J Med Chem 1999, 42: 1203-12.
3. Dragovich, P.S., Prins, T.J., Zhou, R. et al. Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 4. Incorporation of P1 lactam moieties as L-glutamine replacements. J Med Chem 1999, 42: 1213-24.
4. Couch, R.B. Rhinoviruses. In: Fields Virology. B.N. Fields et al. (Eds.), Raven Publishers, Philadelphia, 1996, 713-34.
5. Andries, K., Dewindt, B., Snoeks, J., Willebrords, R., Stokbroekx, R., Lewi, P.J. A comparative test of fifteen compounds against all known human rhinovirus serotypes as a basis fora more rational screening program. Antivir Res 1991, 16: 213-25.
6. Rossmann, M.G. Viral cell recognition and entry. Protein Sci 1994, 3: 1712-25.
7. Wang, Q.M. Design of rhinovirus protease inhibitors for treatment of common cold. Drugs Fut 2000, 25: in preparation.
8. Dragovich, P.S., Webber, S.E., Fuhrman, S.A. et al. Structure-based design of irreversible peptidyl and peptidomimetic human rhinovirus 3C protease inhibitors. 217th ACS Natl Meet (March 21-25, Anaheim) 1999, Abst MEDI 264.
9. Matthews, D.A., Dragovich, P.S., Webber, S.E. et al. Structure-assisted design of mechanism-based irreversible inhibitors of human rhinovirus 3C protease with potent antiviral activity against multiple rhinovirus serotypes. Proc Natl Acad Sci USA 1999, 96: 11000-7.
10. Patick, A.K., Binford, S.L., Brothers, M.A. et al. In vitro antiviral activity of AG7088, a potent inhibitor of human rhinovirus 3C protease. Antimicrob Agents Chemother 1999, 43: 2444-50.
11. Kaiser, L., Crump, C., Patick, A.K., Zalman, L.S., Hayden, F.G. Comparative in vitro antirhinoviral activity of AG7088 and pleconaril. 39th Intersci Conf Antimicrob Agents Chemother (Sept 26-29, San Francisco) 1999, Abst H276.
12. Zalman, L.S., Brothers, M.A., Dragovich, P.S., Prins, T.J., Marakovits, J.T., Zhou, R., Tikhe, J., Webber, S.E., Worland, S.T., Patick, A.K. Novel anti-human rhinovirus compounds directed at 3C protease can inhibit cytokine production in infected cells. 38th Intersci Conf Antimicrob Agents Chemother (Sept 24-27, San Diego) 1998, Abst H-62.
13. Pithavala, Y.K., Hsyu, P.H., Gersten, M., Crampton, S., Penning, C.A., Daniels, R.G., Zhang, K., Paradiso, L., Kerr, B.M. Phase I evaluation of the safety and pharmacokinetics of intranasal AG7088, a novel investigational 3C protease inhibitor. 39th Intersci Conf Antimicrob Agents Chemother (Sept 26-29, San Francisco) 1999, Abst H275.
14. Hsyu, P., Pithavala, Y., Gersten, M., Crampton, S., Zhang, K., Paradiso, L., Buonarati, M. Nasal disposition of AG7088, a rhinovirus 3C protease inhibitor, after multiple intranasal doses in healthy volunteers. Annu Meet Am Assoc Pharm Sci (Nov 14-18, New Orleans) 1999, Abst 3636.
15. Agouron's AG-7088 successfully completes phase II rhinovirus trial. DailyDrugNews.com (Daily Essentials) Dec 14, 1999.
16. Patick, A.K., Ford, C.E., Brothers, M.A. et al. Evaluation of the antiviral activity of irreversible inhibitors of human rhinovirus 3C protease, a novel target for antiviral intervention. 38th Intersci Conf Antimicrob Agents Chemother (Sept 24-27, San Diego) 1998, Abst H-61.
17. AG-7088 development status. Agouron Pharmaceuticals, Inc. Company Communication Nov 23, 1999.